| Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer MF Fraga, E Ballestar, A Villar-Garea, M Boix-Chornet, J Espada, ... Nature genetics 37 (4), 391-400, 2005 | 2397 | 2005 |
| Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia T Schenk, WC Chen, S Göllner, L Howell, L Jin, K Hebestreit, HU Klein, ... Nature medicine 18 (4), 605-611, 2012 | 706 | 2012 |
| Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease RM Hill, S Kuijper, JC Lindsey, K Petrie, EC Schwalbe, K Barker, ... Cancer cell 27 (1), 72-84, 2015 | 214 | 2015 |
| Differentiation therapy of acute myeloid leukemia: past, present and future K Petrie, A Zelent, S Waxman Current opinion in hematology 16 (2), 84-91, 2009 | 203 | 2009 |
| Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia–associated TEL-AML1 oncoprotein F Guidez, K Petrie, AM Ford, H Lu, CA Bennett, A MacGregor, ... Blood, The Journal of the American Society of Hematology 96 (7), 2557-2561, 2000 | 194 | 2000 |
| The histone deacetylase 9 gene encodes multiple protein isoforms K Petrie, F Guidez, L Howell, L Healy, S Waxman, M Greaves, A Zelent Journal of Biological Chemistry 278 (18), 16059-16072, 2003 | 182 | 2003 |
| New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK G Barone, J Anderson, ADJ Pearson, K Petrie, L Chesler Clinical Cancer Research 19 (21), 5814-5821, 2013 | 157 | 2013 |
| Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity F Mussai, S Egan, S Hunter, H Webber, J Fisher, R Wheat, C McConville, ... Cancer research 75 (15), 3043-3053, 2015 | 109 | 2015 |
| Targeting of AML1-ETO in t (8; 21) leukemia by oridonin generates a tumor suppressor–like protein T Zhen, CF Wu, P Liu, HY Wu, GB Zhou, Y Lu, JX Liu, Y Liang, KK Li, ... Science translational medicine 4 (127), 127ra38-127ra38, 2012 | 107 | 2012 |
| Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells EF Farias, K Petrie, B Leibovitch, J Murtagh, MB Chornet, T Schenk, ... Proceedings of the National Academy of Sciences 107 (26), 11811-11816, 2010 | 79 | 2010 |
| Selective inhibition of SIN3 corepressor with avermectins as a novel therapeutic strategy in triple-negative breast cancer YJ Kwon, K Petrie, BA Leibovitch, L Zeng, M Mezei, L Howell, V Gil, ... Molecular cancer therapeutics 14 (8), 1824-1836, 2015 | 78 | 2015 |
| Lineage restriction of the RARα gene expression in myeloid differentiation J Zhu, CM Heyworth, A Glasow, QH Huang, K Petrie, M Lanotte, G Benoit, ... Blood, The Journal of the American Society of Hematology 98 (8), 2563-2567, 2001 | 66 | 2001 |
| Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma MEM Dolman, E Poon, ME Ebus, IJM den Hartog, CJM van Noesel, ... Clinical Cancer Research 21 (22), 5100-5109, 2015 | 64 | 2015 |
| DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia A Glasow, A Barrett, K Petrie, R Gupta, M Boix-Chornet, DC Zhou, ... Blood, The Journal of the American Society of Hematology 111 (4), 2374-2377, 2008 | 55 | 2008 |
| Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice VS Gil, G Bhagat, L Howell, J Zhang, CH Kim, S Stengel, F Vega, A Zelent, ... Disease models & mechanisms 9 (12), 1483-1495, 2016 | 51 | 2016 |
| p53 loss in MYC-driven neuroblastoma leads to metabolic adaptations supporting radioresistance O Yogev, K Barker, A Sikka, GS Almeida, A Hallsworth, LM Smith, Y Jamin, ... Cancer research 76 (10), 3025-3035, 2016 | 40 | 2016 |
| The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML M Kahl, A Brioli, M Bens, F Perner, A Kresinsky, U Schnetzke, A Hinze, ... Leukemia 33 (11), 2628-2639, 2019 | 35 | 2019 |
| Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer N Bansal, K Petrie, R Christova, CY Chung, BA Leibovitch, L Howell, V Gil, ... Oncotarget 6 (33), 34087, 2015 | 34 | 2015 |
| Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy A Zelent, K Petrie, Z Chen, R Lotan, M Lübbert, MS Tallman, R Ohno, ... Cancer research 65 (4), 1117-1123, 2005 | 29 | 2005 |
| Retinoic acid receptor γ is a therapeutically targetable driver of growth and survival in prostate cancer K Petrie, Z Urban‐Wójciuk, Y Sbirkov, A Graham, A Hamann, G Brown Cancer Reports 3 (6), e1284, 2020 | 23 | 2020 |
Tino SchenkDepartment of Hematology and Medical Oncology, Clinic of Internal Medicine II, Jena University在 med.uni-jena.de 的电子邮件经过验证
